- Ocumetics (TSXV:OTC), an ophthalmic solutions provider, has met its latest milestone with its intraocular lens technology, demonstrating accommodative power using 3D-printed lenses under simulated conditions
- The achievement follows progress across numerous key areas announced in April
- Ocumetics is a Canadian research and product development company specializing in vision correction solutions
- Ocumetics stock has given back 4.84 per cent year-over-year and 49.14 per cent since 2021
Ocumetics (TSXV:OTC), an ophthalmic solutions provider, has met its latest milestone with its intraocular lens technology, following progress across numerous key areas announced in April.
Ocumetics’ pre-clinical intraocular lens fits within the eye’s natural lens compartment, allowing for seamless focusing from distance to near, potentially eliminating the need for traditional corrective lenses.
According to Thursday’s news release, the company demonstrated accommodative power in a lab setting using 3D-printed lenses under simulated bodily conditions, defining accommodative power as “the eye’s ability to focus between near and far distances following lens replacement surgery.”
The results validate the company’s design on a theoretical level and clear the way for initial human trials in summer 2025, followed by a development roadmap envisioning phase-1 clinical trials in 2026, phase-2 trials in 2027 and potential approval by the United States Food and Drug Administration in 2028.
Leadership insights
“These results represent a critical milestone for Ocumetics and for the future of ophthalmology,” Dean Burns, Ocumetics’ chief executive officer, said in a statement. “The data supports our confidence in the platform and strengthens our commitment to delivering a lens that not only corrects vision but restores the natural focusing ability lost with age. Our next steps will continue to focus on preparing for our first-in-human studies, planned for summer 2025.”
“This achievement validates years of innovation and perseverance. Demonstrating measurable accommodative power in a laboratory setting using our moulded lens design confirms the foundational science behind the Ocumetics Lens,” added Garth Webb, Ocumetics’ founder and chief scientific officer. “We are now closer than ever to redefining how we approach vision restoration.”
About Ocumetics
Ocumetics is a Canadian research and product development company specializing in vision correction solutions.
Ocumetics stock (TSXV:OTC) is unchanged trading at C$0.30 as of 9:49 am ET. The stock has given back 4.84 per cent year-over-year and 49.14 per cent since 2021.
Join the discussion: Find out what everybody’s saying about this healthcare technology stock on the Ocumetics Technology Corp. Bullboard and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
